The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes

NCT06408532 on ClinicalTrials.gov · last registry update 2024-05-10

An unusually large phase 4: 256 participants, more than double the 75 typical for the stage. Its estimated completion date, 30 October 2024, has passed with no update to the record. Primary outcome, as filed: Hemoglobin A1c (HbA1c). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Peking University People's Hospital
Sponsor type: Other
Enrollment: 256
Started: 2024-04-30
Primary completion: 2024-10-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Hemoglobin A1c (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.